Stay updated on Gilead Sciences Press Releases
Sign up to get notified when there's something new on the Gilead Sciences Press Releases page.

Latest updates to the Gilead Sciences Press Releases page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a Newsroom entry for August 4, 2026 announcing Gilead Sciences' Second Quarter 2026 Financial Results. Removed the June 12, 2026 entry about rapid Remdesivir donation for Ebola relief from the Newsroom.SummaryDifference4%

- Check19 days agoChange DetectedNo changes are present in the provided data for the News page. The page content snapshot remains unchanged.SummaryDifference0.5%

- Check26 days agoChange DetectedSeveral July 2026 News Releases headlines were added (including CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer and the Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026). At the same time, older June 2026 items were removed from the list, updating the feed to reflect current and past news in the timeline.SummaryDifference4%

- Check55 days agoChange DetectedAdds two new News Releases announcing Trodelvy approvals in the U.S. and Europe, and removes two older items (Ouro Medicines acquisition and Seladelpar PBC trial results) from the News Releases list.SummaryDifference4%

- Check63 days agoChange DetectedA new press release about FDA acceptance of Gilead’s investigational once-weekly Yeztugo is added to the News Releases, while an older press release about Livdelzi (Seladelpar) Phase 3 data is removed, reflecting an update to the News page.SummaryDifference4%

- Check70 days agoChange DetectedFour new News Releases were added (June 12, June 11, and June 8, 2026), expanding coverage of Gilead's latest activities, while four older items from May 21–22, 2026 were removed from the list.SummaryDifference4%

Stay in the know with updates to Gilead Sciences Press Releases
Enter your email address, and we'll notify you when there's something new on the Gilead Sciences Press Releases page.